From
http://norml.org/index.cfm?Group_ID=6724November 9, 2005 - Barcelona, Spain
Barcelona, Spain: Spanish health officials have approved the importation and use of Sativex, an oral spray consisting of natural cannabis extracts, for select patients suffering from Multiple Sclerosis (MS), neuropathic pain, and other conditions.
Produced by the British biotechnology firm GW Pharmaceuticals and marketed by Bayer, Sativex is a whole plant medicinal cannabis extract containing precise doses of the cannabinoids THC and cannabidiol (CBD), as well as naturally existing terpenoids (oils) and flavonoids (antioxidants). In clinical trials, Sativex has been demonstrated to alleviate numerous MS-associated symptoms compared to placebo, including pain, muscle spasms, and bladder incontinence. The drug is available by prescription in Canada and is pending regulatory approval in the United Kingdom.
Six hundred patients, including those suffering from MS, chronic pain, cancer, and the AIDS wasting syndrome, will be provided Sativex under the Spanish Ministry of Health's compassionate access program. The government's limited approval of the drug marks the first time Europeans will have legal access to Sativex outside of a clinical trial.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500.